KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Intravitreal aflibercept 8 mg in patients from Japan with diabetic macular edema: 48-week subgroup analysis of the PHOTON trial.

Kiyoshi Suzuma, Toshinori Murata, Masahiko Shimura, Shigeo Yoshida, Genichiro Kishino, Alyson J Berliner, Karen W Chu, Kimberly Reed, Robert Vitti, Yenchieh Cheng, Delia Voronca, Rafia Bhore, Sergio Leal, Peter Morgan-Warren, Andrea Schulze, Ursula Schmidt-Ott, Masato Kobayashi, Taiji Sakamoto, PHOTON Investigators

Jpn J Ophthalmol 70(1) 123-138

PMID41452566
PMCIDPMC12948817
DOI10.1007/s10384-025-01271-7
发表日期2025-12-26
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:Fig. 1:森林图/亚组分析图;Fig. 2:森林图/亚组分析图;Fig. 3:森林图/亚组分析图;Fig. 4:森林图/亚组分析图。
摘要

摘要

PURPOSE: In the pivotal PHOTON trial of patients with diabetic macular edema (DME), aflibercept 8 mg administered every 12 (8q12) and 16 (8q16) weeks demonstrated similar visual and anatomic outcomes with no new safety signals to aflibercept 2 mg every 8 weeks (2q8). We conducted a prespecified subgroup analysis to assess the efficacy, durability, and safety of aflibercept 8 mg in the Japanese patients from PHOTON. STUDY DESIGN: Prespecified subgroup analysis of the Phase 3 PHOTON trial (NCT04429503). METHODS: Adult patients with DME were randomized 1:2:1 to receive intravitreal aflibercept 2q8, 8q12, or 8q16 following initial monthly doses. Patients randomized to 8q12 and 8q16 were eligible for dose regimen modification. The primary endpoint was change from baseline in best-corrected visual acuity (BCVA) at Week 48. Prespecified efficacy and safety outcomes at/through Week 48 are reported, segmented by Japan versus the rest of world (non-Japan). RESULTS: In the Japan and non-Japan subgroups, respectively, mean changes in BCVA were +7.0 and +9.0 (8q12), +7.4 and +7.9 (8q16), and +8.0 and +9.4 (2q8) letters at Week 48; differences in least squares means were -0.30 and -0.64 letters between 8q12 and 2q8 and +0.17 and -1.76 letters between 8q16 and 2q8; ocular treatment-emergent adverse events were reported in 32.4% and 31.6% (8q12), 35.3% and 28.8% (8q16), and 30.0% and 27.2% (2q8) of patients. CONCLUSION: Improvements in BCVA at Week 48 were generally similar with aflibercept 8 mg versus 2 mg in this subgroup analysis of Japanese and non-Japanese patients with DME, suggesting that the primary findings from PHOTON may be generalized to the Japanese population.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Arithmetic mean change and LS mean change from baseline in BCVA through Week 48 in the (a) Japan and (b) non-Japan subgroups of PHOTON. Full analysis set. Mean change from baseline in BCVA through Week 48 in the Japan subgroup ( a ) and the non-Japan subgroup ( b ) are presented in the top panels. Data are arithmetic means of observed data before relevant intercurrent events, as previously defined [ 24 ]. The number of patients included in the analysis, after accounting for relevant intercurrent events and missing data, are shown for each timepoint. LS mean change from baseline in BCVA at Week 48 in the Japan subgroup ( a ) and the non-Japan subgroup ( b ) are presented in the bottom panels. LS means were generated using MMRM, based on observed data before relevant intercurrent events, with baseline BCVA as a covariate; treatment group, visit, stratification variables (geographic region [Japan vs. rest of world], baseline CRT [< 400 μm vs. ≥ 400 μm], and previous treatment for DME [yes vs. no]) as fixed factors; and terms for the interaction between baseline BCVA and visit and the interaction between treatment and visit. Missing data were covered by the MMRM. Error bars indicate 95% CIs. 2q8 aflibercept 2 mg every 8 weeks, 8q12 aflibercept 8 mg every 12 weeks, 8q16 aflibercept 8 mg every 16 weeks, BCVA best-corrected visual acuity, CI confidence interval, CRT central retinal thickness, DME diabetic macular edema, LS least squares, MMRM mixed model for repeated measures
非 KM Figure
Fig. 2Proportion of aflibercept 8 mg-treated patients who maintained their randomized dosing intervals through Week 48 in the ( a ) Japan and ( b ) non-Japan subgroups of PHOTON. Percentages are based on the number of patients randomized to 8q12 or 8q16 who completed the Week 48 visit segmented by Japan versus non-Japan. Values may not add up to 100% due to rounding. a Patients in the safety analysis set who completed Week 48. b Patients randomly assigned to aflibercept 8q16 whose dosing intervals were shortened to 8q12, excluding those whose dosing intervals were later shortened to aflibercept 8 mg Q8 from 8q12. 8q12 aflibercept 8 mg every 12 weeks, 8q16 aflibercept 8 mg every 16 weeks, Q8 every 8 weeks, Q12 every 12 weeks, Q16 every 16 weeks
非 KM Figure
Fig. 3Proportion of patients in the ( a ) Japan and ( b ) non-Japan subgroups of PHOTON with ≥ 2-step DRSS improvement from baseline at Weeks 12 and 48. Full analysis set. The proportion of patients with ≥ 2-step improvement in DRSS score at Weeks 12 and 48 in the Japan ( a ) and the non-Japan ( b ) subgroups. Adjusted difference (95% CI) between treatment groups at Week 48 is shown above the bars. The adjusted difference and 95% CI at Week 48 were calculated using the Mantel-Haenszel weighting scheme adjusted for stratification variables (geographic region [Japan vs. rest of the world], baseline CRT [< 400 μm vs. ≥ 400 μm], previous treatment for DME [yes vs. no]). Missing data and excluded data due to intercurrent events were imputed using the last observation carried forward approach. 2q8 aflibercept 2 mg every 8 weeks, 8q12 aflibercept 8 mg every 12 weeks, 8q16 aflibercept 8 mg every 16 weeks, CI confidence interval, CRT central retinal thickness, DME diabetic macular edema, DRSS Diabetic Retinopathy Severity Scale
非 KM Figure
Fig. 4Mean change and LS mean change from baseline in CRT through Week 48 in the ( a ) Japan and ( b ) non-Japan subgroups of PHOTON. Full analysis set. Mean change from baseline in CRT through Week 48 in the Japan ( a ) and the non-Japan ( b ) subgroups are presented in the top panels. Data are arithmetic means of observed data before relevant intercurrent events. The number of patients included in the analysis, after accounting for relevant intercurrent events and missing data, are provided for each timepoint. LS mean change from baseline in CRT at Week 48 in the Japan ( a ) and the non-Japan ( b ) subgroup are presented in the bottom panels. Data are LS means that were generated using MMRM, based on observed data before relevant intercurrent events, with baseline CRT as a covariate; treatment group, visit, stratification variables (geographic region [Japan vs. rest of the world], baseline CRT [< 400 μm vs. ≥ 400 μm], and previous treatment for diabetic macular edema [yes vs. no]) as fixed factors; and terms for the interaction between baseline CRT and visit and the interaction between treatment and visit. Missing data were covered by the MMRM. Retinal thickness measurements were based on optical coherence tomography segmentation from the inner limiting membrane to the retinal pigment epithelium. 2q8 aflibercept 2 mg every 8 weeks, 8q12 aflibercept 8 mg every 12 weeks, 8q16 aflibercept 8 mg every 16 weeks, CI confidence interval, CRT central retinal thickness, LS least squares, MMRM mixed model for repeated measures
非 KM Figure